Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
Shani Paluch‐Shimon, Olivia Pagani, Ann H. Partridge, et al.
The Breast (2017) Vol. 35, pp. 203-217
Closed Access | Times Cited: 230

Showing 1-25 of 230 citing articles:

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber, et al.
Annals of Oncology (2010) Vol. 21, pp. v9-v14
Open Access | Times Cited: 2803
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, S. Kyriakides, Shinji Ohno, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1194-1220
Open Access | Times Cited: 1717
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Prudence A. Francis, Olivia Pagani, Gini F. Fleming, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 2, pp. 122-137
Open Access | Times Cited: 555
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
Francesca Poggio, Marco Bruzzone, Marcello Ceppi, et al.
Annals of Oncology (2018) Vol. 29, Iss. 7, pp. 1497-1508
Open Access | Times Cited: 384
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
Matteo Lambertini, Halle C. F. Moore, Robert Leonard, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 19, pp. 1981-1990
Open Access | Times Cited: 334
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2020) Vol. 31, Iss. 6, pp. 674-696
Open Access | Times Cited: 221
Diagnosis and Treatment of Breast Cancer in Young Women
Lorenzo Rossi, Calogero Mazzara, Olivia Pagani
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 12
Closed Access | Times Cited: 147
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2022) Vol. 33, Iss. 11, pp. 1097-1118
Open Access | Times Cited: 108
What Is Known about Breast Cancer in Young Women?
Jie Wei Zhu, Parsa Charkhchi, Shadia Adekunte, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1917-1917
Open Access | Times Cited: 58
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Olivia Pagani, Prudence A. Francis, Gini F. Fleming, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 12, pp. 1293-1303
Open Access | Times Cited: 124
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
Matteo Lambertini, Oranite Goldrat, Arlindo R. Ferreira, et al.
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 237-243
Open Access | Times Cited: 120
Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application
Matteo Lambertini, Florence Horicks, Lucia Del Mastro, et al.
Cancer Treatment Reviews (2018) Vol. 72, pp. 65-77
Closed Access | Times Cited: 101
<p>A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of <em>BRCA</em>-mutated breast cancer</p>
Carol Forbes, Debra Fayter, Shelley de Kock, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 2321-2337
Open Access | Times Cited: 99
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
JNCI Journal of the National Cancer Institute (2018) Vol. 111, Iss. 1, pp. 86-94
Open Access | Times Cited: 84
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis
Hee Jeong Kim, Seon‐Ok Kim, Rachel A. Freedman, et al.
The Breast (2021) Vol. 61, pp. 77-83
Open Access | Times Cited: 62
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients
Matteo Lambertini, Massimo Di Maïo, Olivia Pagani, et al.
The Breast (2018) Vol. 42, pp. 41-49
Open Access | Times Cited: 82
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230
Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips, et al.
JNCI Journal of the National Cancer Institute (2018) Vol. 111, Iss. 2, pp. 210-213
Open Access | Times Cited: 77
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
Hyun‐Ah Kim, Jong Won Lee, Seok Jin Nam, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 5, pp. 434-443
Open Access | Times Cited: 75
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
Matteo Lambertini, Samuel Martel, Christine Campbell, et al.
Cancer (2018) Vol. 125, Iss. 2, pp. 307-316
Open Access | Times Cited: 63
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Philip D. Poorvu, Shari Gelber, Shoshana M. Rosenberg, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 7, pp. 725-733
Open Access | Times Cited: 62
Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy
Zeev Blumenfeld
Clinical Medicine Insights Reproductive Health (2019) Vol. 13
Open Access | Times Cited: 57
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olga Caramelo, Cristina Silva, Francisco Caramelo, et al.
Hereditary Cancer in Clinical Practice (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 55
Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China
Jingfeng Jing, Feng Ran, Xiaojun Zhang, et al.
Breast Cancer Research and Treatment (2020) Vol. 181, Iss. 2, pp. 435-443
Closed Access | Times Cited: 51
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
Francesca Poggio, Marco Bruzzone, Marcello Ceppi, et al.
ESMO Open (2018) Vol. 3, Iss. 4, pp. e000361-e000361
Open Access | Times Cited: 55
Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach
Mahmoud Salama, Antoinette Anazodo, Teresa K. Woodruff
Annals of Oncology (2019) Vol. 30, Iss. 11, pp. 1760-1775
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top